+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.

Age: 12Years +All GendersPhase 3
478 locations